[go: up one dir, main page]

PE2099A1 - Derivados de acido hidroxamico - Google Patents

Derivados de acido hidroxamico

Info

Publication number
PE2099A1
PE2099A1 PE1997000874A PE00087497A PE2099A1 PE 2099 A1 PE2099 A1 PE 2099A1 PE 1997000874 A PE1997000874 A PE 1997000874A PE 00087497 A PE00087497 A PE 00087497A PE 2099 A1 PE2099 A1 PE 2099A1
Authority
PE
Peru
Prior art keywords
alkyl
aryl
formula
compounds
piridyl
Prior art date
Application number
PE1997000874A
Other languages
English (en)
Inventor
Georg Kottirsch
Ulf Neumann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9620572.9A external-priority patent/GB9620572D0/en
Priority claimed from GBGB9706667.4A external-priority patent/GB9706667D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE2099A1 publication Critical patent/PE2099A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIEREN A COMPUESTOS DE FORMULA (I), EN DONDE: R1 ES A-(O-(CR5H)n)m-O-CH2-; R2 ES ALQUILO C3-C12, ALQUENILO C3-C12, ENTRE OTROS, DE PREFERENCIA ES CICLOHEXILO, FENILO, 4-METILFENILO, 4-METOXIFENILO o ISOBUTILO; R3 ES ALQUILO C1-C10 OPCIONALMENTE SUSTITUIDO, ARILO C6-C14 o INDOLILMETILO, DE PREFERENCIA ES BENCILO o t-BUTILO; R4 ES METILO, PIRIDILO o X-Y, EN DONDE "X" ES MORFOLINO, PIRIDILO o ARILO; "Y" ES ALQUILENO C1-C12, DONDE HASTA CUATRO (-CH2-) ESTAN REEMPLAZADAS OPCIONALMENTE CON -CO-, -NH-, -SO2- u -O-; R4 DE PREFERENCIA ES METILO o MORFOLINOCARBONIL-ALQUILO C1-C6; R5 ES H, ALQUILO C1-C10 OPCIONALMENTE SUSTITUIDO, ALQUENILO C2-C6, ENTRE OTROS; "A" ES H, ALQUILO C1-C10, ARILO C6-C14, ARILO C6-C14(ALQUILO C1-C6), ENTRE OTROS; n ES 1; 2; 3 o 4; m ES 0; 1; 2 o 3. TAMBIEN SE REFIERE AL PROCEDIMIENTO DE PREPARACION Y A LOS COMPUESTOS INTERMEDIOS DE FORMULA (III) Y (IV). LOS COMPUESTOS DE FORMULA (I) ACTUAN INHIBIENDO LA LIBERACION DEL FACTOR DE NECROSIS TUMORAL (TNFO), A TRAVES DE LA SUPRESION DE LA ENZIMA CONVERTASA DEL TNF, SIENDO UTILES EN EL TRATAMIENTO DE INFECCIONES AGUDAS, CAQUEXIA, ENTRE OTROS; e INHIBIENDO LAS ENZIMAS METALOPROTEASAS DE MATRIZ, POR EJEMPLO, COLAGENASA, ESTROMELISINA Y GELATINASA, SIENDO UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, OSTEOARTRITIS, ENTRE OTROS
PE1997000874A 1996-10-02 1997-09-30 Derivados de acido hidroxamico PE2099A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9620572.9A GB9620572D0 (en) 1996-10-02 1996-10-02 Organic compounds
GBGB9706667.4A GB9706667D0 (en) 1997-04-02 1997-04-02 Organic compounds

Publications (1)

Publication Number Publication Date
PE2099A1 true PE2099A1 (es) 1999-02-08

Family

ID=26310147

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000874A PE2099A1 (es) 1996-10-02 1997-09-30 Derivados de acido hidroxamico

Country Status (29)

Country Link
EP (1) EP0929517B1 (es)
JP (1) JP3444898B2 (es)
KR (1) KR20000048811A (es)
CN (1) CN1101807C (es)
AR (1) AR009103A1 (es)
AT (1) ATE219050T1 (es)
AU (1) AU726065B2 (es)
BR (1) BR9712255A (es)
CA (1) CA2267415A1 (es)
CO (1) CO4900034A1 (es)
CZ (1) CZ113999A3 (es)
DE (1) DE69713354T2 (es)
DK (1) DK0929517T3 (es)
ES (1) ES2178759T3 (es)
HK (1) HK1021637A1 (es)
HU (1) HUP9903892A3 (es)
ID (1) ID22212A (es)
IL (1) IL129166A0 (es)
MY (1) MY127926A (es)
NO (1) NO313457B1 (es)
NZ (1) NZ334908A (es)
PE (1) PE2099A1 (es)
PL (1) PL188518B1 (es)
PT (1) PT929517E (es)
RU (1) RU2196131C2 (es)
SI (1) SI0929517T1 (es)
SK (1) SK43099A3 (es)
TR (1) TR199900725T2 (es)
WO (1) WO1998014424A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003294917A1 (en) * 2002-12-20 2004-07-14 Novartis Ag Device and method for delivering mmp inhibitors
EP2287326A1 (en) 2003-08-08 2011-02-23 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
WO2005086915A2 (en) 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
CN1951912B (zh) * 2005-10-18 2010-05-05 上海五洲药业股份有限公司 手性脂环烃异羟肟酸衍生物的制备方法
GB0818907D0 (en) * 2008-10-15 2008-11-19 Isis Innovation Histone lysine demethylase inhibitors
RU2021110237A (ru) * 2016-04-18 2021-05-06 Виворион Терапьютикс Аг Новые ингибиторы меприна альфа и бета

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
DE19581347T1 (de) * 1994-01-20 1996-12-05 British Biotech Pharm Metalloproteinase-Inhibitoren
WO1995019961A1 (en) * 1994-01-22 1995-07-27 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
GB9416897D0 (en) * 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors

Also Published As

Publication number Publication date
HUP9903892A2 (hu) 2000-03-28
TR199900725T2 (xx) 1999-07-21
MY127926A (en) 2006-12-29
IL129166A0 (en) 2000-02-17
PL188518B1 (pl) 2005-02-28
SK43099A3 (en) 1999-08-06
RU2196131C2 (ru) 2003-01-10
PT929517E (pt) 2002-10-31
SI0929517T1 (en) 2002-10-31
NO991559D0 (no) 1999-03-30
KR20000048811A (ko) 2000-07-25
BR9712255A (pt) 1999-08-24
WO1998014424A1 (en) 1998-04-09
CA2267415A1 (en) 1998-04-09
AU726065B2 (en) 2000-10-26
DE69713354D1 (de) 2002-07-18
JP3444898B2 (ja) 2003-09-08
ID22212A (id) 1999-09-16
EP0929517B1 (en) 2002-06-12
ES2178759T3 (es) 2003-01-01
NO991559L (no) 1999-03-30
CZ113999A3 (cs) 1999-06-16
ATE219050T1 (de) 2002-06-15
AU4706897A (en) 1998-04-24
NO313457B1 (no) 2002-10-07
AR009103A1 (es) 2000-03-08
JP2000508338A (ja) 2000-07-04
CN1232447A (zh) 1999-10-20
CO4900034A1 (es) 2000-03-27
HK1021637A1 (en) 2000-06-23
NZ334908A (en) 2000-10-27
DK0929517T3 (da) 2002-10-07
HUP9903892A3 (en) 2000-04-28
EP0929517A1 (en) 1999-07-21
PL332477A1 (en) 1999-09-13
DE69713354T2 (de) 2002-12-05
CN1101807C (zh) 2003-02-19

Similar Documents

Publication Publication Date Title
YU20094A (sh) Hidrazidi 1-h-indol-3-sirćetne kisleine kao inhibitori spla2
DK0659174T3 (da) Derivater af valproinsyre og 2-valproensyreamider samt deres anvendelse som antikonvulsive midler
CY1106497T1 (el) Νεες αρυλοξυ-αλκυλ-διαλκυλαμινες
ES2149043T3 (es) Compuestos glicerolipidicos utiles para la transferencia de una substancia activa a una celula diana.
ES2061480T3 (es) Ariloxi- y arilaciloxi-metilcetonas inhibidoras de tiol proteasas.
FI971312A0 (fi) Uudet prostaglandiinisyntaasin estäjät
DE69705480D1 (de) Verwendung von Oestrogenagonisten und -antagonisten zur Herstellung eines Medikaments zur Behandlung von Atherosklerose, unabhängig von Lipidsenkung
DK0898562T3 (da) Hydroxamsyrederivater til anvendelse ved behandling af sygdomme relateret til bindevævsdegenerering
ATE246171T1 (de) Aminosulfonylcarbamate
DE69911980D1 (de) Pyrimidinonderivate zur behandlung von atheroscleros
EA200100809A1 (ru) 2,3,4,5-тетрагидро-1h-[1,4]бензодиазепин-3-гидроксамовые кислоты как ингибиторы матриксных металлопротеиназ
PE20051004A1 (es) Compuestos de biaril sulfonamidas como inhibidores de metaloproteinasas
DK116480A (da) Fremgangsmaade til fremstilling af substituerede chromoner
DE60021368D1 (de) Ppar-(gamma) agonisten zur behandlung von type ii diabetes
EA200300927A1 (ru) Новый способ промышленного синтеза тетрасложных эфиров 5-[бис(карбоксиметил)амино]-3-карбоксиметил-4-циано-2-тиофенкарбоновой кислоты и применение для синтеза бивалентных солей ранелиновой кислоты и их гидратов
PE2099A1 (es) Derivados de acido hidroxamico
MA20331A1 (fr) Procede pour l'obtention de derives de l'acide methylene diphosphorique ayant des proprietes anti-rhumatismales .
ATE37543T1 (de) Acylierte saccharin-derivate.
ATE290062T1 (de) Verwendung schaumarmer, tensidhaltiger percarbonsaüre-mittel zur cip-desinfektion
EA200201027A1 (ru) Новый способ синтеза n-[(s)-1-карбоксибутил]-(s)-аланиновых эфиров и применение в синтезе периндоприла
ES2181772T3 (es) Compuesto de eter, su utilizacion e intermediario para la obtencion de este compuesto.
DK1205476T3 (da) Fremgangsmåde til syntese af N-(mercaptoacyl)-aminosyrederivater ud fra alfa-substituerede acrylsyrer
DK0904270T3 (da) Dihydrobenzofuran og beslægtede forbindelser anvendelige som antiinflammatoriske midler
BR9813923A (pt) N n - bis(sulfonil) hidrazinas úteis como agentes antineoplásicos
ATE41149T1 (de) Substituierte furazane.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed